INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Observational study / 2011

Higher serum enterolactone levels were linked to significantly reduced risk of death in postmenopausal breast cancer patients.

Researchers assessed the prognosis of 1,140 postmenopausal breast cancer patients followed for a median of 6.1 years. Median enterolactone levels were 17.0 nmol/L in deceased patients and 21.4 nmol/L in living patients, with 162 total deaths confirmed. Higher serum enterolactone was associated with significantly reduced risk of death (HR per 10 nmol/L increment, 0.94; P = .04; HR for the highest quartile, 0.58; 95% CI, 0.34 to 0.99). For distant disease, the HR was 0.94 per 10 nmol/L (P = .08) and 0.62 (95% CI, 0.35 to 1.09) in the highest quartile. The highest quartile was associated with significantly reduced death risk only in estrogen receptor-negative tumors (HR, 0.27; 95% CI, 0.08 to 0.87), not in estrogen receptor-positive tumors (HR, 0.91; 95% CI, 0.45 to 1.84).

Shows an association, not proof of cause and effect.

Study type
Prospective cohort study
Who was studied
1,140 postmenopausal breast cancer patients aged 50-74 years diagnosed 2002-2005
What was measured
Overall survival and distant disease-free survival

THE PAPER

Serum enterolactone and prognosis of postmenopausal breast cancer.

Buck K, Vrieling A, Zaineddin AK, Becker S, Hüsing A, Kaaks R, Linseisen J, Flesch-Janys D, Chang-Claude J. J Clin Oncol, 2011.

PubMed 21900115 ↗DOI 10.1200/jco.2011.34.6478 ↗

Cancer

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.